Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov;25(6):637-45.
doi: 10.1097/CCO.0000000000000006.

Current status of interleukin-10 and regulatory T-cells in cancer

Kristen L Dennis  1 , Nichole R Blatner, Fotini Gounari, Khashayarsha Khazaie
Affiliations
Review

Current status of interleukin-10 and regulatory T-cells in cancer

Kristen L Dennis et al. Curr Opin Oncol. 2013 Nov.

Abstract

Purpose of review: Tumor growth elicits antigen-specific cytotoxic as well as immune suppressive responses. Interleukin-10 (IL-10) is a key immune-suppressive cytokine produced by regulatory T-cells and by helper T-cells. Here, we review pleiotropic functions of IL-10 that impact the immune pathology of cancer.

Recent findings: The role of IL-10 in cancer has become less certain with the knowledge of its immune stimulatory functions. IL-10 is needed for T-helper cell functions, T-cell immune surveillance, and suppression of cancer-associated inflammation. By promoting tumor-specific immune surveillance and hindering pathogenic inflammation, IL-10 is emerging as a key cytokine in the battle of the host against cancer.

Summary: IL-10 functions at the cross-roads of immune stimulation and immune suppression in cancer. Immunological mechanisms of action of IL-10 can be ultimately exploited to develop novel and effective cancer therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Overarching hypothesis
Colon cancer is driven by microbial associated. Typically this is a TH17 inflammation that is controlled by IL-10-expressing T-cells and Tregs. There is also a general consensus that cancer is controlled by immune surveillance and TH1 response. Ultimately, disease outcome is the product of both control of inflammation and effective immune surveillance. IL-10 is essential for both processes.
See this image and copyright information in PMC

References

    1. De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora JP, Wolfel T, Sibille C, Chomez P, Boon T. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc Natl Acad Sci U S A. 1988;85:2274–2278. - PMC - PubMed
    1. Degiovanni G, Lahaye T, Herin M, Hainaut P, Boon T. Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones. Eur J Immunol. 1988;18:671–676. - PubMed
    1. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med. 1991;173:1373–1384. - PMC - PubMed
    1. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum Buschenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A. 1989;86:2804–2808. - PMC - PubMed
    1. Bruno L, Kirberg J, von Boehmer H. On the cellular basis of immunological T cell memory. Immunity. 1995;2:37–43. - PubMed

Publication types